Alemtuzumab demonstrates improvement in MRI outcomes across baseline subgroups versus subcutaneous interferon beta-1a in relapsingremitting multiple sclerosis patients who relapsed on prior therapy

The requested reference [d6c92e029ceebed1e0edf83205562f3a10e3d056] no longer exists in our database. It has been replaced by the current reference: [400eac5c139c64b9acdf26c3aae47f2728a97be6]

Authors
Category Primary study
ConferenceJournal of Neurology
Year 2014
This article has no abstract
Epistemonikos ID: 24a1b4047378790e7531a885f1d394fd67ddfda1
First added on: Apr 30, 2026